Welcome to our dedicated page for Whitehawk Therapeutics SEC filings (Ticker: WHWK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Whitehawk Therapeutics, Inc. (Nasdaq: WHWK) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Whitehawk is a clinical-stage oncology therapeutics company focused on antibody-drug conjugate (ADC) cancer treatments, and its filings offer insight into financial results, development plans and corporate activities related to this strategy.
Among the key documents available are current reports on Form 8-K, which Whitehawk has used to furnish press releases announcing quarterly financial results and recent highlights. These filings reference information such as research and development spending, progress toward Investigational New Drug (IND) submissions for ADC programs like HWK-007 and HWK-016, and updates on the company’s three-asset ADC portfolio targeting PTK7, MUC16 and SEZ6.
On this page, users can also locate Whitehawk’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain more detailed discussions of the company’s oncology pipeline, risk factors, and financial condition. For investors interested in governance and compensation matters, proxy materials and related filings can provide additional context on board and executive oversight of the ADC development strategy.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand major updates without having to parse every page. Real-time updates from the SEC’s EDGAR system ensure that new WHWK filings, including future 10-Ks, 10-Qs and 8-Ks, appear promptly. Users can also review insider transaction reports on Form 4, when available, to see reported trades by directors and officers.
Together, these resources give a structured view of how Whitehawk reports its financial performance, clinical progress and corporate decisions to regulators and the market.
Whitehawk Therapeutics, Inc. (WHWK) reported that its chief financial officer, Scott M. Giacobello, received two equity awards on September 15, 2026. He was granted a stock option for 118,476 shares of common stock at an exercise price of $4.09 per share, expiring on September 15, 2036; 25% of the option vests on the one-year anniversary of the September 15, 2026 Vesting Commencement Date, and 1/48 of the total vests monthly thereafter until fully vested after four years. He also received 118,476 restricted stock units, each representing one share of common stock, which will vest 100% on the one-year anniversary of the same Vesting Commencement Date, correcting an earlier Form 4 that had an incorrect vesting schedule. No Rule 10b5-1 trading plan is reported.
Whitehawk Therapeutics, Inc. (WHWK) reported that Chief Technical Operations Officer Bryan Ball received two equity awards on September 15, 2026: a stock option covering 91,633 shares of common stock with an exercise price of $4.09 per share, and an award of 91,633 restricted stock units, each representing one share of common stock.
The stock option vests over four years, with 25% of the shares vesting on the one-year anniversary of the Vesting Commencement Date of September 15, 2026, and the remainder vesting in equal monthly installments so that all shares are vested by the four-year anniversary. The restricted stock unit award vests 100% on the one-year anniversary of the same Vesting Commencement Date, assuming Mr. Ball continues as a service provider. The amended filing corrects an earlier Form 4 that had reported an incorrect vesting schedule for the restricted stock units. No transactions were made under a Rule 10b5-1 trading plan.
Whitehawk Therapeutics, Inc. (WHWK) reported that Chief Scientific Officer David Dornan received equity awards on September 15, 2026. He was granted a stock option for 85,887 shares of common stock at an exercise price of $4.09 per share, expiring on September 15, 2036, vesting 25% after one year from the Vesting Commencement Date and monthly thereafter over four years, subject to continued service. He also received 85,887 restricted stock units, each representing one share of common stock, which will vest 100% on the one-year anniversary of the Vesting Commencement Date, subject to continued service. The amendment corrects the previously reported vesting schedule for the RSU award. No Rule 10b5-1 trading plan is reported.
Whitehawk Therapeutics, Inc. (WHWK) reported that its chief executive officer, David James Lennon, received a stock option grant for 193,957 shares of common stock at an exercise price of $4.09 per share and a separate grant of 193,957 restricted stock units on September 15, 2026. The option vests 25% on the one-year anniversary of the September 15, 2026 vesting commencement date, with the remainder vesting in equal monthly installments over the following three years, and expires on September 15, 2036. The RSU award is structured so that 100% of the shares vest on the one-year anniversary of the same vesting commencement date, and this amendment corrects an earlier report that had shown an incorrect vesting schedule.
Whitehawk Therapeutics, Inc. (WHWK) reported that Chief Medical Officer Margaret Dugan received two equity awards on September 15, 2026: a stock option and a restricted stock unit (RSU) grant, each covering 81,250 shares of Common Stock, with no Rule 10b5-1 trading plan indicated.
The stock option has an exercise price of $4.09 per share and expires on September 15, 2036; subject to Dr. Dugan continuing as a Service Provider, 25% of the option vests on the one-year anniversary of the September 15, 2026 Vesting Commencement Date and the remaining 75% vests in equal monthly installments over the following three years. The RSU award represents a contingent right to receive one share of Common Stock per unit and, as corrected in this amended filing, is scheduled to vest 100% on the one-year anniversary of the same September 15, 2026 Vesting Commencement Date, contingent on continued service.
Whitehawk Therapeutics, Inc. (WHWK) reported equity awards to Chief Executive Officer David James Lennon on September 15, 2026. He received a stock option for 193,957 shares of Common Stock at an exercise price of $4.09 per share, expiring September 15, 2036, and 193,957 Restricted Stock Units, each RSU representing one share of Common Stock.
Both awards vest based on continued service: for the option, 25% vests on the one-year anniversary of the September 15, 2026 Vesting Commencement Date and 1/48 of the total vests monthly thereafter until fully vested after four years; for the RSUs, 25% vests on each of the first four anniversaries of that Vesting Commencement Date.
Whitehawk Therapeutics, Inc. (WHWK) reported that its Chief Financial Officer, Scott M. Giacobello, received two equity awards on September 15, 2026. He was granted stock options covering 118,476 shares of common stock at an exercise price of $4.09 per share, and a separate award of 118,476 Restricted Stock Units, each RSU representing one share of common stock. Both awards vest over time starting from a Vesting Commencement Date of September 15, 2026, subject to his continued service, with the options vesting monthly over four years and the RSUs vesting in four equal annual installments.
Whitehawk Therapeutics, Inc. (symbol: WHWK) is the issuer of record for a Form 4 filing submitted to the SEC. Dugan Margaret reported acquisition or exercise transactions in this Form 4 filing.
Whitehawk Therapeutics, Inc. (WHWK) reported that its Chief Medical Officer, Margaret Dugan, received equity-based compensation on September 15, 2026. She was granted options to purchase shares of common stock and a separate award of restricted stock units, each covering 81,250 shares, with multi-year vesting tied to continued service.
Whitehawk Therapeutics, Inc. (symbol: WHWK) is the issuer of record for a Form 4 filing submitted to the SEC. Dornan David reported acquisition or exercise transactions in this Form 4 filing.
Whitehawk Therapeutics, Inc. (WHWK) reported that Chief Scientific Officer David Dornan received new equity awards. On September 15, 2026 he was granted options to purchase 85,887 shares of common stock at $4.09 per share, expiring September 15, 2036, plus 85,887 restricted stock units. Both awards vest over four years starting from a Vesting Commencement Date of September 15, 2026, contingent on continued service, and no Rule 10b5-1 trading plan is reported.
Whitehawk Therapeutics, Inc. (WHWK) reported equity compensation grants to its Chief Technical Operations Officer, Bryan Ball. On September 15, 2026, he received a stock option for 91,633 shares of common stock at an exercise price of $4.09 per share, expiring on September 15, 2036. The option vests 25% on the one-year anniversary of the Vesting Commencement Date of September 15, 2026, with the remaining shares vesting in equal monthly installments over the following three years, subject to continued service. On the same date, he also received 91,633 restricted stock units, each representing one share of common stock, vesting 25% on the first anniversary of the Vesting Commencement Date and 25% on each of the next three anniversaries, also conditioned on continued service. No Rule 10b5-1 trading plan is reported for these awards.